Donn G. Wishka

Donn G. Wishka

Auto-generated profile, based on publicly available information

Donn G. Wishka

Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DWDonn G. Wishka
Donn G. Wishka
DWDaniel Walker
Daniel Walker
KYKaren M. Yates
Karen M. Yates
SRSteven C. Reitz
Steven C. Reitz
SJShaojuan Jia
Shaojuan Jia
BRBruce N. Rogers
Bruce N. Rogers

7 August 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JMJoel Morris
Joel Morris
MKMark W. Kunkel
Mark W. Kunkel
SWStephen L. White
Stephen L. White
DWDonn G. Wishka
Donn G. Wishka
OLOmar D. Lopez
Omar D. Lopez
BTBeverly A. Teicher
Beverly A. Teicher
The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public (https://ioa.cancer.gov) and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.

16 September 2024
Verified
Other
Open access
JMJoel Morris
Joel Morris
MKMark W. Kunkel
Mark W. Kunkel
SWStephen L. White
Stephen L. White
DWDonn G. Wishka
Donn G. Wishka
OLOmar D. Lopez
Omar D. Lopez
BTBeverly A. Teicher
Beverly A. Teicher
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource

16 September 2024
Verified
Other
Open access
JMJoel Morris
Joel Morris
MKMark W. Kunkel
Mark W. Kunkel
SWStephen L. White
Stephen L. White
DWDonn G. Wishka
Donn G. Wishka
OLOmar D. Lopez
Omar D. Lopez
BTBeverly A. Teicher
Beverly A. Teicher
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource

16 September 2024
Verified
Other
Open access
JMJoel Morris
Joel Morris
MKMark W. Kunkel
Mark W. Kunkel
SWStephen L. White
Stephen L. White
DWDonn G. Wishka
Donn G. Wishka
OLOmar D. Lopez
Omar D. Lopez
BTBeverly A. Teicher
Beverly A. Teicher
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource